Is Botox Filler safe for all skin types?

Botox and HA fillers are FDA/KFDA-approved for Fitzpatrick skin types I through VI, with clinical trials including over 3,700 participants across diverse ethnicities. Safety profiles remain consistent regardless of skin type. However, patients with active infections, autoimmune conditions, or neuromuscular disorders face contraindications that require medical screening before any injectable treatment.

What are the side effects of Botox Filler?

Bruising occurs in 19-24% of injection sites and resolves within 5-7 days. Swelling peaks at 24-48 hours post-treatment. Headache affects approximately 11% of Botox patients. Rare complications include eyelid ptosis in fewer than 2% of cases and vascular occlusion in under 0.001% of filler procedures, both requiring prompt clinical management.

How do I know if a clinic is qualified?

Over 15 KFDA-approved botulinum toxin products are available in Korea, and qualified clinics use only these regulated formulations. Verify that the clinic operates under the Medical Service Act, employs licensed physicians, opens product vials in your presence, and maintains emergency reversal agents including hyaluronidase on-site for immediate use.

What certifications should I look for?

Korean clinics require a medical license (issued after 6 years of medical education plus 1 year of internship) for injectable procedures. An Aesthetic Medicine Specialist designation indicates advanced training in cosmetic procedures. The clinic should display its MFDS registration, maintain documented product lot tracking, and have physicians with over 500 supervised injection procedures completed.

Are there long-term risks?

A 6-year KFDA post-market surveillance study found no cumulative toxicity from repeated Botox treatments administered every 3-6 months. Long-term filler risks include granuloma formation in approximately 0.1-1% of patients, typically presenting 6-24 months post-injection. HA fillers remain reversible with hyaluronidase regardless of how long they have been in tissue.

Botox Filler Safety & Side Effects

How Botox and Fillers Work: Mechanisms and Safety Profiles

Botulinum toxin type A (Botox) temporarily blocks acetylcholine release at the neuromuscular junction, reducing muscle contraction for 3-6 months per session. The KFDA (Korea's Ministry of Food and Drug Safety) has approved multiple botulinum toxin products for cosmetic use, including Botox (onabotulinumtoxinA), Dysport, and Korean-manufactured alternatives such as Nabota. Each product undergoes rigorous clinical trials demonstrating safety and efficacy before market authorization.

Dermal fillers, primarily hyaluronic acid-based products like Juvederm and Belotero, restore volume by binding water molecules beneath the skin surface. These fillers integrate into tissue at depths of 1-4mm depending on the product viscosity and target area. The reversibility of HA fillers with hyaluronidase provides an additional safety mechanism that non-HA fillers like Radiesse and Sculptra do not offer.

Common Side Effects and Their Duration

Botox Side Effects

Clinical data from over 3,700 treated patients shows bruising occurs in approximately 19% of Botox injection sites, resolving within 5-7 days. Headache affects roughly 11% of patients and typically subsides within 24-48 hours. Eyelid ptosis, the most commonly cited concern, occurs in fewer than 2% of cases when proper injection technique is used, with spontaneous resolution within 2-4 weeks. Asymmetry from uneven diffusion occurs in about 3% of treatments and can be corrected with a follow-up adjustment at 14 days.

Filler Side Effects

Dermal filler injections produce swelling in 90% of patients, peaking at 24-48 hours and resolving within 3-7 days. Bruising affects 19-24% of treatment areas. Nodule formation occurs in approximately 2-5% of cases, more frequently with thicker products used in deep tissue planes. Vascular occlusion, the most serious complication, occurs in fewer than 0.001% of procedures but requires immediate intervention with hyaluronidase within 4-6 hours. Seo et al. reported a comprehensive safety analysis in the Journal of Cosmetic Dermatology. 2023;22(4):1203-1210. doi:10.1111/jocd.15592

Contraindications and Pre-Treatment Screening

Absolute contraindications for Botox include pregnancy, breastfeeding, known hypersensitivity to botulinum toxin, and neuromuscular disorders such as myasthenia gravis or Lambert-Eaton syndrome. For dermal fillers, active bacterial or viral skin infections at the injection site, autoimmune connective tissue diseases, and a history of severe allergic reactions to HA products require avoidance. Patients taking blood thinners should discontinue aspirin or NSAIDs 7-10 days before treatment to reduce bruising risk.

A qualified practitioner conducts a thorough medical history review, assesses facial anatomy, and documents any previous injectable treatments before proceeding. In Korea, clinics operating under KFDA oversight maintain standardized screening protocols that include allergy history, medication review, and photographic documentation.

KFDA Regulation and Clinic Standards in Korea

Korea's MFDS (Ministry of Food and Drug Safety) regulates all injectable products through a multi-phase approval process requiring Phase III clinical trials with a minimum of 300 participants. Post-market surveillance extends for 6 years after approval. Korea has over 15 KFDA-approved botulinum toxin products as of 2026, more than any other country, reflecting both market demand and regulatory rigor. Kim et al. detailed the Korean regulatory framework in Archives of Plastic Surgery. 2021;48(5):515-523. doi:10.5999/aps.2021.00710

Clinics in Korea operate under the Medical Service Act, requiring physician-administered injections with documented product lot numbers and expiration dates. Aesthetic Medicine Specialists perform injectable procedures following standardized protocols that include emergency preparedness with hyaluronidase and epinephrine on-site. RE:BERRY maintains these standards across all branches, with each practitioner completing over 500 supervised injection procedures before independent practice.

Minimizing Risks: What Patients Should Know

Selecting a licensed clinic with KFDA-approved products eliminates the risk of counterfeit or diluted formulations, which account for an estimated 8-12% of injectables in unregulated markets. Patients should verify that the product vial is opened in their presence, check the batch number, and confirm the expiration date. Avoiding alcohol for 48 hours before treatment and applying arnica gel post-procedure reduces bruising duration by approximately 30%.

Follow-up appointments at 14 days allow the practitioner to assess results, address any asymmetry, and document outcomes. For filler treatments, knowing the specific product used is critical because only HA-based fillers can be dissolved with hyaluronidase in emergency situations. Keeping a personal record of product names, volumes, and treatment dates enables safer future procedures at any clinic.